Completed OBSERVATIONAL NCT01331720

Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation (DESCARTES)

Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation Protocols Which Are the Most Common in Clinical Practice Using High Purified Gonadotrophins (u-FSH-HP y u-hMG-HP) in IVF/ICSI

Sponsor: Ferring Pharmaceuticals

Conditions STERILITY

Interventions hMG-HP

Updated 7 times since 2017 Last updated: Apr 7, 2011 Started: Nov 30, 2007 Primary completion: Mar 31, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01331720, this observational or N/A phase trial focuses on STERILITY and remains completed. Sponsored by Ferring Pharmaceuticals, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals
Ferring SAU

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albacete, Spain , Alicante, Spain , Badajoz, Spain , Castellon, Spain , Elche, Spain , Gijón, Spain , Mallorca, Spain , Murcia, Spain , Málaga, Spain , Navarra, Spain and 4 more locations